Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
2254
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.This transaction
This tender offerCounterpartyMEDIPAL HOLDINGS CORPORATION
Disclosing companyS.T.CORPORATION
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Acquisition priceTotal planned sale proceeds: ¥2,254 million
Type of ConsiderationCash
Tender offer price¥6,650 per common share
Tender offer period12 May 2026 to 7 July 2026
Amount of extraordinary income (loss)Gain on sale of investment securities: ¥1,794 million; expected to be recognized as extraordinary income in the fiscal year ending March 2027
Impact on Business Performance
The Company expects to recognize a ¥1,794 million gain on the sale of investment securities as extraordinary income in its non-consolidated and consolidated financial statements for the fiscal year ending March 2027.
Procedures and assumptions
Conditions Precedent to ExecutionThe public tender offer is successfully completed at the planned purchase price
| Item | Details |
|---|---|
| Transaction name | This tender offer |
| Counterparty name | MEDIPAL HOLDINGS CORPORATION |
| Name of the Subject Company | PALTAC CORPORATION |
| Acquisition price | Total planned sale proceeds: ¥2,254 million |
| Type of Consideration | Cash |
| Tender offer price | ¥6,650 per common share |
| Tender offer period | 12 May 2026 to 7 July 2026 |
| Number of shares acquired | 339,000 shares; number of voting rights: Not disclosed |
| Amount of extraordinary income (loss) | Gain on sale of investment securities: ¥1,794 million; expected to be recognized as extraordinary income in the fiscal year ending March 2027 |
| Impact on Business Performance | The Company expects to recognize a ¥1,794 million gain on the sale of investment securities as extraordinary income in its non-consolidated and consolidated financial statements for the fiscal year ending March 2027. |
| Date of board resolution | 19 June 2026 |
| Execution Date / Effective Date | 14 July 2026 (settlement commencement date) |
| Conditions Precedent to Execution | The public tender offer is successfully completed at the planned purchase price |
Items this document does not state (19)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioMinimum number of shares to be purchasedVoting rights ownership percentageFunding arrangementsGoodwill amountContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company determined that the policy concerning cross-shareholdings, the PALTAC board of directors' support, the planned purchase price and other terms were reasonable.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.